Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Polyamine production is downstream and upstream of oncogenic PI3K signalling and contributes to tumour cell growth.

Rajeeve V, Pearce W, Cascante M, Vanhaesebroeck B, Cutillas PR.

Biochem J. 2013 Mar 15;450(3):619-28. doi: 10.1042/BJ20121525.

PMID:
23330613
3.

Quinazoline based small molecule exerts potent tumour suppressive properties by inhibiting PI3K/Akt/FoxO3a signalling in experimental colon cancer.

Qazi AK, Hussain A, Khan S, Aga MA, Behl A, Ali S, Singh SK, Taneja SC, Shah BA, Saxena AK, Mondhe DM, Hamid A.

Cancer Lett. 2015 Apr 1;359(1):47-56. doi: 10.1016/j.canlet.2014.12.034. Epub 2014 Dec 29.

PMID:
25554016
4.

Phosphatidylinositol Phosphate 5-Kinase Iγ and Phosphoinositide 3-Kinase/Akt Signaling Couple to Promote Oncogenic Growth.

Thapa N, Choi S, Tan X, Wise T, Anderson RA.

J Biol Chem. 2015 Jul 24;290(30):18843-54. doi: 10.1074/jbc.M114.596742. Epub 2015 Jun 12.

5.

Pancreatic tumor suppression by benzyl isothiocyanate is associated with inhibition of PI3K/AKT/FOXO pathway.

Boreddy SR, Pramanik KC, Srivastava SK.

Clin Cancer Res. 2011 Apr 1;17(7):1784-95. doi: 10.1158/1078-0432.CCR-10-1891. Epub 2011 Feb 24. Erratum in: Clin Cancer Res. 2012 May 1;18(9):2719.

7.

PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.

Herzog A, Bian Y, Vander Broek R, Hall B, Coupar J, Cheng H, Sowers AL, Cook JD, Mitchell JB, Chen Z, Kulkarni AB, Van Waes C.

Clin Cancer Res. 2013 Jul 15;19(14):3808-19. doi: 10.1158/1078-0432.CCR-12-2716. Epub 2013 May 2.

8.
9.

Polyamine depletion induces apoptosis through mitochondria-mediated pathway.

Nitta T, Igarashi K, Yamamoto N.

Exp Cell Res. 2002 May 15;276(1):120-8.

PMID:
11978014
10.

A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types.

Jamieson S, Flanagan JU, Kolekar S, Buchanan C, Kendall JD, Lee WJ, Rewcastle GW, Denny WA, Singh R, Dickson J, Baguley BC, Shepherd PR.

Biochem J. 2011 Aug 15;438(1):53-62. doi: 10.1042/BJ20110502.

11.

A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.

Korkolopoulou P, Levidou G, Trigka EA, Prekete N, Karlou M, Thymara I, Sakellariou S, Fragkou P, Isaiadis D, Pavlopoulos P, Patsouris E, Saetta AA.

BJU Int. 2012 Dec;110(11 Pt C):E1237-48. doi: 10.1111/j.1464-410X.2012.11569.x. Epub 2012 Oct 29.

13.

3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma.

Maurer M, Su T, Saal LH, Koujak S, Hopkins BD, Barkley CR, Wu J, Nandula S, Dutta B, Xie Y, Chin YR, Kim DI, Ferris JS, Gruvberger-Saal SK, Laakso M, Wang X, Memeo L, Rojtman A, Matos T, Yu JS, Cordon-Cardo C, Isola J, Terry MB, Toker A, Mills GB, Zhao JJ, Murty VV, Hibshoosh H, Parsons R.

Cancer Res. 2009 Aug 1;69(15):6299-306. doi: 10.1158/0008-5472.CAN-09-0820. Epub 2009 Jul 14.

14.

Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.

Shukla S, Maclennan GT, Hartman DJ, Fu P, Resnick MI, Gupta S.

Int J Cancer. 2007 Oct 1;121(7):1424-32.

15.

FoxO transcription factors promote AKT Ser473 phosphorylation and renal tumor growth in response to pharmacologic inhibition of the PI3K-AKT pathway.

Lin A, Piao HL, Zhuang L, Sarbassov dos D, Ma L, Gan B.

Cancer Res. 2014 Mar 15;74(6):1682-93. doi: 10.1158/0008-5472.CAN-13-1729. Epub 2014 Jan 21.

16.

Reconstitution of the mammalian PI3K/PTEN/Akt pathway in yeast.

Rodríguez-Escudero I, Roelants FM, Thorner J, Nombela C, Molina M, Cid VJ.

Biochem J. 2005 Sep 1;390(Pt 2):613-23.

17.

PTEN-deficient cancers depend on PIK3CB.

Wee S, Wiederschain D, Maira SM, Loo A, Miller C, deBeaumont R, Stegmeier F, Yao YM, Lengauer C.

Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13057-62. doi: 10.1073/pnas.0802655105. Epub 2008 Aug 28.

19.

Effects of inhibitors of ornithine and S-adenosylmethionine decarboxylases on L6 myoblast proliferation.

Stoscheck CM, Erwin BG, Florini JR, Richman RA, Pegg AE.

J Cell Physiol. 1982 Feb;110(2):161-8.

PMID:
6802862
20.

Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia.

Blalock WL, Navolanic PM, Steelman LS, Shelton JG, Moye PW, Lee JT, Franklin RA, Mirza A, McMahon M, White MK, McCubrey JA.

Leukemia. 2003 Jun;17(6):1058-67.

PMID:
12764369

Supplemental Content

Support Center